Upper School Intersession 2025

Thomas W. Chalberg, PhD is an investor, scientist, and biotechnology entrepreneur. He is currently Managing Director of Polymerase Capital, where his investments have included Genascence Corporation and Exhaura. Prior to this, Dr. Chalberg was the Founder & CEO of SightGlass Vision, which was acquired by a joint venture between CooperVision and EssilorLuxottica in February 2021. Previously, Dr. Chalberg was Chief Operating Officer of Oncorus (NASDAQ: ONCR), Founder/CEO of Avalanche Biotechnologies (NASDAQ: ADVM), and a member of the ophthalmology team at Genentech. Dr. Chalberg currently holds Board of Directors positions at Ethris GmbH, Chameleon Biosciences, and iRenix. He has received awards and recognition from the Foundation Fighting Blindness and the World Economic Forum for his contributions to biotechnology. He received his AB in biochemistry from Harvard College, PhD in genetics from Stanford University School of Medicine, and MBA from the Haas School of Business at the University of California, Berkeley.